| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.095 | 0.05 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.05 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | 0.11 | 0.05 |
| mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | -0.067 | 0.05 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.084 | 0.05 |
| mRNA | Salubrinal | GDSC1000 | pan-cancer | AAC | 0.1 | 0.05 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.06 |